US clinical trials are now under way for personalized cancer vaccines made using a patient's own cancer cells. Already being marketed in Australia and Holland, these custom-made treatments are injected over a series of weeks or months and have proven to be far less toxic than traditional therapies.
The personalized cancer vaccines work in theory much like a flu shot. The vaccine is introduced into the patient's body over several weeks, forcing the body's immune system to recognize the intruder. Early evidence shows that the body "remembers" the cancer cells and attacks them if they return after treatment.
Most research is now being focused on late-stage cancer patients who have few remaining treatment options. It is still unknown whether personalized vaccines for cancer patients can be produced on a large scale at a reasonable price. Three companies, Avax, Intracel, and Antigenics, are hoping to have a commercial version of their vaccines available within the next two to three years. Current US trials include kidney, colon, late-stage melanoma, and ovarian cancers. For more information about clinical trials go to www.avax-tech.com and www.antigenics.com.
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Revolutionizing Infection Prevention: How Fewer Hand Hygiene Observations Can Boost Patient Safety
December 23rd 2024Discover how reducing hand hygiene observations from 200 to 50 per unit monthly can optimize infection preventionists' time, enhance safety culture, and improve patient outcomes.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.